1. A study protocol for HEalth-Related quality of life-intervention in ... - Trials
4 nov 2020 · This clinical trial aims to evaluate the efficacy and safety of XBYRT in improving CRF and quality of life (QOL) of cancer survivors.
Cancer-related fatigue (CRF) is a debilitating condition which commonly affects cancer survivors. The management of CRF remains a challenge due to the lack of effective pharmacological interventions. Traditional Chinese medicine (TCM) could be a potential therapeutic option for CRF. The modified Xiang Bei Yang Rong Tang (XBYRT) is a TCM herbal decoction, formulated to improve fatigue symptoms in cancer survivors. This clinical trial aims to evaluate the efficacy and safety of XBYRT in improving CRF and quality of life (QOL) of cancer survivors. This is a single centre, randomized, double-blind, placebo-controlled, parallel trial. Eighty cancer survivors will be recruited and randomized to receive the XBYRT or placebo decoction, in a ratio of 1:1. Participants will consume the XBYRT/placebo decoction daily for 8 weeks and undergo assessments at baseline and 4, 8 and 10 weeks after baseline. The participants will be assessed for patient-reported outcomes (PRO), blood biomarkers and adverse events at each time point. The primary outcome is the overall health and QOL status, at 8 weeks follow-up. The secondary outcomes are the effects of XBYRT on fatigue levels, cancer-related cognitive impairment and QOL, as assessed by PRO. The incidence of adverse events and the effects of the XBYRT decoction on blood biomarkers associated with CRF will also be evaluated. Efficacy and safety outcomes from this trial will provide important clinical data to guide future large-scale randomized co...
2. Vol 9, No 3 (March 31, 2020) - Translational Cancer Research
31 mrt 2020 · Translational Cancer Research publishes the results of novel research investigations including risk assessment, cellular and prevention, ...
Translational Cancer Research publishes the results of novel research investigations including risk assessment, cellular and prevention, detection, diagnosis and treatment of human cancers.
3. Yunfei Yuan | Liver Surgery - Sun Yat-sen University Cancer Center
He is the pioneer in China to evaluate the hepatic functional reserve for patients with hepatocellular carcinoma with one parameter, retention rate of ...
sun yat-sen university cancer center,Sun Yat-sen University Cancer Center,SYSUCC
4. Yoon Jung Chang - Cancer Research and Treatment
Satisfaction with and perceived benefits of needs-assessment related to rehabilitation after chemotherapy among patients with breast cancer
Advanced Search
5. Chinese Journal of Cancer: Cancer Conmmunications
This thematic series discusses the molecular classifications of gastric cancer by the Cancer Genome Atlas (TCGA) and the Asian Cancer Research Group (ACRG) as ...
Cancer Communications(Chinese Journal of Cancer© is indexed in SCI and PubMed. The CJC publishes original research, reviews, perspectives, supplements, and spotlights in all areas of cancer research.
6. Vol 11, No 4 (April 29, 2022) - Translational Lung Cancer Research
29 apr 2022 · Rui Fu, Jia-Tao Zhang, Rong-Rong Chen, Hong Li, Zai-Xian Tai, Hao-Xiang Lin, Jian Su, Xiang-Peng Chu, Chao Zhang, Zhen-Bin Qiu, Zi-Hao Chen, ...
Translational Lung Cancer Research provides practical up-to-date information on prevention, early detection, diagnosis, and treatment of lung cancer.
7. Xie Chuanmiao | Medical Imaging - Sun Yat-sen University Cancer Center
Currently, he serves as the director for the Department of Imaging at the Sun Yat-sen University Cancer Center, Chief Physician and Doctoral Advisor. He has ...
sun yat-sen university cancer center,Sun Yat-sen University Cancer Center,SYSUCC
8. [PDF] 中 医 肿 瘤 治 疗 - Maciocia Online
Yin and Jing. This has both a Chinese and a Western aspect. From the point of view of Chinese medicine, when cancer manifests with masses, there ...
9. Chinese Journal of Cancer Research: Home
Chinese Journal of Cancer Research (CJCR) is published by AME Publishing Company (www.amepc.org) in association with Chinese Anti-Cancer Association.
Chinese Journal of Cancer Research (CJCR) is published by AME Publishing Company (www.amepc.org) in association with Chinese Anti-Cancer Association. CJCR is a bi-monthly peer-reviewed journal in English, and is an international journal devoted to the life sciences and medical sciences.
10. Eukaryotic translation initiation factor 5A2 regulates the migration and ...
26 apr 2016 · ... Ying Cai, Jun Yu, Xian-Ning Zhang. ... cancer cells treated with GC7 or NAC for 24 h was assessed. We found ...
// Rong-Rong Liu 1, * , Ya-Su Lv 1, * , Yue-Xiao Tang 1 , Yan-Fang Wang 1 , Xiao-Ling Chen 2 , Xiao-Xiao Zheng 1 , Shang-Zhi Xie 1 , Ying Cai 1 , Jun Yu 3 , Xian-Ning Zhang 1 1 Department of Cell Biology and Medical Genetics, Research Center for Molecular Medicine, National Education Base for Basic Medical Sciences, Institute of Cell Biology, Zhejiang University School of Medicine, Hangzhou, 310058, China 2 Department of Biological Chemistry, Zhejiang Chinese Medical University, Hangzhou, 310053, China 3 Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Key Laboratory of Multi-Organ Transplantation of Ministry of Public Health, Hangzhou, 310003, China * These authors contributed equally to this work Correspondence to: Xian-Ning Zhang, e-mail: zhangxianing@zju.edu.cn Jun Yu, e-mail: Dr.yujun@gmail.com Keywords: eukaryotic translation initiation factor 5A2, reactive oxygen species, epithelial-mesenchymal transition, migration, hepatocellular carcinoma Received: September 24, 2015 Accepted: February 28, 2016 Published: March 23, 2016 ABSTRACT Eukaryotic translation initiation factor 5A2 ( eIF5A2 ) has been identified as a critical gene in tumor metastasis. Research has suggested that reactive oxygen species (ROS) serve as signaling molecules in cancer cell proliferation and migration. However, the mecha...
11. Correction: Postoperative Chemoradiotherapy versus ... - PLOS
1 aug 2013 · ... Cancer with D2 Lymphadenectomy: A Meta-Analysis. Yuan-Yuan Huang, Qiong Yang, Si-Wei Zhou, Ying Wei, Yan-Xian Chen, De-Rong Xie, Bei Zhang ...
Loading metrics
12. Yoon Jung Choi - Cancer Research and Treatment
Overexpression of circulating CD38+ NK cells in colorectal cancer was associated with lymph node metastasis and poor prognosis ... Ying Duan, Hangrong Fang ...
13. Granzyme B PET Imaging of Combined Chemotherapy and ...
... with immune checkpoint inhibitor (ICI) monotherapy in cancer patients. In ... Results: [18F]AlF-mNOTA-GZP tumor uptake was able to clearly ...
Purpose: Chemotherapeutic adjuvants, such as oxaliplatin (OXA) and 5-fluorouracil (5-FU), that enhance the immune system, are being assessed as strategies to improve durable response rates when used in combination with immune checkpoint inhibitor (ICI) monotherapy in cancer patients. In this study, we explored granzyme B (GZB), released by tumor-associated immune cells, as a PET imaging-based stratification marker for successful combination therapy using a fluorine-18 (18F)-labelled GZB peptide ([18F]AlF-mNOTA-GZP). Methods: Using the immunocompetent CT26 syngeneic mouse model of colon cancer, we assessed the potential for [18F]AlF-mNOTA-GZP to stratify OXA/5-FU and ICI combination therapy response via GZB PET. In vivo tumor uptake of [18F]AlF-mNOTA-GZP in different treatment arms was quantified by PET, and linked to differences in tumor-associated immune cell populations defined by using multicolour flow cytometry. Results: [18F]AlF-mNOTA-GZP tumor uptake was able to clearly differentiate treatment responders from non-responders when stratified based on changes in tumor volume. Furthermore, [18F]AlF-mNOTA-GZP showed positive associations with changes in tumor-associated lymphocytes expressing GZB, namely GZB+ CD8+ T cells and GZB+ NK+ cells. Conclusions: [18F]AlF-mNOTA-GZP tumor uptake, driven by changes in immune cell populations expressing GZB, is able to stratify tumor response to chemotherapeutics combined with ICIs. Our results show that, while the immunomodulatory mode...
